Լյարդաբջջային քաղցկեղ (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Լյարդաբջջային քաղցկեղ" in Armenian language version.

refsWebsite

Global rank Armenian rank

62nih.gov

4^th place

3^rd place

41doi.org

2^nd place

4^th place

12semanticscholar.org

11^th place

428^th place

7archive.org

6^th place

6web.archive.org

1^st place

4worldcat.org

5^th place

10^th place

3who.int

195^th place

49^th place

2medscape.com

719^th place

149^th place

1iarc.fr

4,025^th place

1,125^th place

1mayoclinic.com

3,634^th place

498^th place

1medicinespecifics.com

low place

1zenodo.org

621^st place

1,041^st place

1hepatocellular.org

low place

1aacrjournals.org

8,869^th place

1,975^th place

1uptodate.com

3,771^st place

983^rd place

1lecturio.com

5,619^th place

low place

1acr.org

low place

9,925^th place

1pathologyatlas.ro

low place

1cancerresearchuk.org

8,489^th place

1,817^th place

1aasld.org

low place

1harvard.edu

18^th place

38^th place

1basicmedicalkey.com

low place

9,851^st place

aacrjournals.org

cgd.aacrjournals.org

Huynh H, Chow PK, Ooi LL, Soo KC (2002). «A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation». Cell Growth & Differentiation. 13 (3): 115–122. PMID 11959812. Արխիվացված է օրիգինալից 2021 թ․ ապրիլի 15-ին. Վերցված է 2023 թ․ հունվարի 28-ին. «Our data indicate that loss of autocrine/paracrine IGFBP-3 loops may lead to HCC tumor growth and suggest that modulating production of the IGFs, IGFBP-3, and IGF-IR may represent a novel approach in the treatment of HCC.»

aasld.org

Marrero, JA; Kulik, LM; Sirlin, CB; Zhu, AX; Finn, RS; Abecassis, MM; Roberts, LR; Heimbach, JK (2018 թ․ օգոստոս). «Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases» (PDF). Hepatology. 68 (2): 723–750. doi:10.1002/hep.29913. PMID 29624699. S2CID 4666537.(չաշխատող հղում)

acr.org

«Li-Rads». Արխիվացված է օրիգինալից 2017 թ․ հուլիսի 11-ին. Վերցված է 2014 թ․ փետրվարի 4-ին.

archive.org

Llovet JM, Brú C, Bruix J (1999). «Prognosis of hepatocellular carcinoma: the BCLC staging classification». Seminars in Liver Disease. 19 (3): 329–38. doi:10.1055/s-2007-1007122. PMID 10518312.
Katyal, Sanjeev; Oliver, James H.; Peterson, Mark S.; Ferris, James V.; Carr, Brian S.; Baron, Richard L. (2000). «Extrahepatic Metastases of Hepatocellular Carcinoma». Radiology. 216 (3): 698–703. doi:10.1148/radiology.216.3.r00se24698. PMID 10966697.
Cillo, Umberto; Vitale, Alessandro; Bassanello, Marco; Boccagni, Patrizia; Brolese, Alberto; Zanus, Giacomo; Burra, Patrizia; Fagiuoli, Stefano; Farinati, Fabio; Rugge, Massimo; d'Amico, Davide Francesco (2004 թ․ փետրվար). «Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma». Annals of Surgery. 239 (2): 150–9. doi:10.1097/01.sla.0000109146.72827.76. PMC 1356206. PMID 14745321.
Tanabe, KK; Curley, SA; Dodd, GD; Siperstein, AE; Goldberg, SN (2004 թ․ փետրվարի 1). «Radiofrequency ablation: the experts weigh in». Cancer. 100 (3): 641–50. doi:10.1002/cncr.11919. PMID 14745883.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Tateishi, R; Shiina, S; Teratani, T; Obi, S; Sato, S; Koike, Y; Fujishima, T; Yoshida, H; Kawabe, T; Omata, M (2005 թ․ մարտի 15). «Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases». Cancer. 103 (6): 1201–9. doi:10.1002/cncr.20892. PMID 15690326. S2CID 37178385.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Chen, Min-Shan; Li, Jin-Qing; Zheng, Yun; Guo, Rong-Ping; Liang, Hui-Hong; Zhang, Ya-Qi; Lin, Xiao-Jun; Lau, Wan Y (2006). «A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma». Annals of Surgery. 243 (3): 321–8. doi:10.1097/01.sla.0000201480.65519.b8. PMC 1448947. PMID 16495695.
Yamamoto, Junji; Okada, Shuichi; Shimada, Kazuaki; Okusaka, Takushi; Yamasaki, Susumu; Ueno, Hideki; Kosuge, Tomoo (2001). «Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection». Hepatology. 34 (4): 707–713. doi:10.1053/jhep.2001.27950. PMID 11584366.

basicmedicalkey.com

Table 37.2 Արխիվացված 2020-02-24 Wayback Machine in: Sternberg, Stephen (2012). Sternberg's diagnostic surgical pathology. Place of publication not identified: LWW. ISBN 978-1-4511-5289-0. OCLC 953861627.

cancerresearchuk.org

«BCLC staging system and the Child-Pugh system ;Liver cancer ; Cancer Research UK». www.cancerresearchuk.org.

doi.org

Forner A, Llovet JM, Bruix J (2012). «Hepatocellular carcinoma». The Lancet. 379 (9822): 1245–1255. doi:10.1016/S0140-6736(11)61347-0. PMID 22353262. S2CID 24927898.
Alter MJ (2007). «Epidemiology of hepatitis C virus infection». World Journal of Gastroenterology. 13 (17): 2436–41. doi:10.3748/wjg.v13.i17.2436. PMC 4146761. PMID 17552026.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
White DL, Kanwal F, El-Serag HB (2012). «Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review». Clinical Gastroenterology and Hepatology. 10 (12): 1342–59. doi:10.1016/j.cgh.2012.10.001. PMC 3501546. PMID 23041539.
El–Serag HB; Hampel H; Javadi F (2006). «the association between diabetes and hepatocellular carcinoma: a systematic review of epidemiological evidence». Clinical Gastroenterology and Hepatology. 4 (3): 369–380. doi:10.1016/j.cgh.2005.12.007. PMID 16527702. «Diabetes is associated with an increased risk for HCC. However, more research is required to examine issues related to the duration and treatment of diabetes, and confounding by diet and obesity»
Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC (2002). «Molecular pathogenesis of human hepatocellular carcinoma». Toxicology. 181–182: 43–47. doi:10.1016/S0300-483X(02)00253-6. PMID 12505283. «Recent studies in our laboratory have identified several potential factors that may contribute to the pathogenesis of HCC...For example, oxyradical overload diseases such as Wilson disease and hemochromatosis result in the generation of oxygen/nitrogen species that can cause mutations in the p53 tumour suppressor gene»
Cheng W, Govindarajan S, Redeker A (1992). «Hepatocellular carcinoma in a case of Wilson's disease». Liver International. 12 (1): 42–45. doi:10.1111/j.1600-0676.1992.tb00553.x. PMID 1314321. «The patient described here was the oldest and only the third female patient with hepatocellular carcinoma complicating Wilson's disease to be reported in the literature»
Wilkinson ML, Portmann B, Williams R (1983). «Wilson's disease and hepatocellular carcinoma: possible protective role of copper». Gut. 24 (8): 767–771. doi:10.1136/gut.24.8.767. PMC 1420230. PMID 6307837. «As copper has been shown to protect against chemically induced hepatocellular carcinoma in rats, this may be the reason for the extreme rarity of hepatocellular carcinoma in patients with Wilson's disease and possibly in other liver diseases with hepatic copper overload»
Shetty, Shrimati; Sharma, Nitika; Ghosh, Kanjaksha (2016 թ․ մարտի 1). «Epidemiology of hepatocellular carcinoma (HCC) in hemophilia». Critical Reviews in Oncology/Hematology (անգլերեն). 99: 129–133. doi:10.1016/j.critrevonc.2015.12.009. ISSN 1040-8428. PMID 26754251.
Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M (2011). «Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures». Journal of Epidemiology. 21 (6): 401–416. doi:10.2188/jea.JE20100190. PMC 3899457. PMID 22041528.
Balogh J, Victor D, Asham E, Burroughs S, Boktour M, Saharia A, Li X, Ghobrial M, Monsour H (2016). «Hepatocellular carcinoma: a review». Journal of Hepatocellular Carcinoma. 3: 41–53. doi:10.2147/JHC.S61146. PMC 5063561. PMID 27785449.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN (2010). «Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma». Cancer. 116 (8): 1938–1946. doi:10.1002/cncr.24982. PMC 4123320. PMID 20166205. «Diabetes appears to increase the risk of HCC, and such risk is correlated with a long duration of diabetes. Relying on dietary control and treatment with sulfonylureas or insulin were found to confer the highest magnitude of HCC risk, whereas treatment with biguanides or thiazolidinediones was associated with a 70% HCC risk reduction among diabetics.»
Donadon, Valter (2009). «Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease». World Journal of Gastroenterology. 15 (20): 2506–11. doi:10.3748/wjg.15.2506. PMC 2686909. PMID 19469001. «Our study confirms that type 2 diabetes mellitus is an independent risk factor for HCC and pre-exists in the majority of HCC patients. Moreover, in male patients with type 2 diabetes mellitus, our data shows a direct association of HCC with insulin and sulphanylureas treatment and an inverse relationship with metformin therapy.»{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Donadon V, Balbi M, Ghersetti M, և այլք: (2009). «Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease». World Journal of Gastroenterology. 15 (20): 2506–11. doi:10.3748/wjg.15.2506. PMC 2686909. PMID 19469001.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Siegel A, Zhu AX (2009). «Metabolic Syndrome and hepatocellular carcinoma». Cancer. 115 (24): 5651–5661. doi:10.1002/cncr.24687. PMC 3397779. PMID 19834957. «The majority of 'cryptogenic' HCC in the United States is attributed to nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome... It is predicted that metabolic syndrome will lead to large increases in the incidence of HCC over the next decades. A better understanding of the relation between these two diseases ultimately should lead to improved screening and treatment options for patients with HCC.»
Stickely F, Hellerbrand C (2010). «Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications». Gut. 59 (10): 1303–1307. doi:10.1136/gut.2009.199661. PMID 20650925. S2CID 31016985. «Based on the known association of NAFLD with IR and MS, approximately two-thirds of the patients were obese and/or diabetic, 4 and a remarkable 25% of these patients had no cirrhosis... Therefore, it is particularly worrying that the most persuasive evidence for an association between NAFLD and HCC derives from studies on the risk of HCC in patients with metabolic syndrome»
Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H (2006). «Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells». Biochemical Pharmacology. 71 (10): 1435–1448. doi:10.1016/j.bcp.2006.02.006. PMID 16530734. «Inhibition of IGF-1R tyrosine kinase (IGF-1R-TK) by NVP-AEW541 induces growth inhibition, apoptosis and cell cycle arrest in human HCC cell lines without accompanying cytotoxicity. Thus, IGF-1R-TK inhibition may be a promising novel treatment approach in HCC.»
Martin NM, Abu Dayyeh BK, Chung RT (2008). «Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage». World Journal of Gastroenterology. 14 (28): 4573–4575. doi:10.3748/wjg.14.4573. PMC 2731289. PMID 18680242. «This is the first reported case of hepatic adenoma re-growth with recidivistic steroid abuse, complicated by life-threatening hemorrhage.»{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Gorayski P, Thompson CH, Subhash HS, Thomas AC (2007). «Hepatocellular carcinoma associated with recreational anabolic steroid use». British Journal of Sports Medicine. 42 (1): 74–75. doi:10.1136/bjsm.2007.03932. PMID 18178686. S2CID 21900098. «Malignant transformation to HCC from a pre-existing hepatic adenoma confirmed by immunohistochemical study has previously not been reported in athletes taking anabolic steroids. Further studies using screening programmes to identify high-risk individuals are recommended.»
Shibata T, Aburatani H (2014). «Exploration of liver cancer genomes». Nat Rev Gastroenterol Hepatol. 11 (6): 340–9. doi:10.1038/nrgastro.2014.6. PMID 24473361. S2CID 8611393.
Chien-Jen Chen; Hwai-I. Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H. Iloeje (2006). «Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level». JAMA. 295 (1): 65–73. doi:10.1001/jama.295.1.65. PMID 16391218.
Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT (2014). «Involvement of DNA damage response pathways in hepatocellular carcinoma». Biomed Res Int. 2014: 1–18. doi:10.1155/2014/153867. PMC 4022277. PMID 24877058.
Nishida N, Kudo M (2013). «Oxidative stress and epigenetic instability in human hepatocarcinogenesis». Dig Dis. 31 (5–6): 447–53. doi:10.1159/000355243. PMID 24281019.
Heimbach, Julie K.; Kulik, Laura M.; Finn, Richard; Sirlin, Claude B.; Abecassis, Michael; Roberts, Lewis R.; Zhu, Andrew; Murad, M. Hassan; Marrero, Jorge (2017 թ․ հունվարի 1). «Aasld guidelines for the treatment of hepatocellular carcinoma». Hepatology (անգլերեն). 67 (1): 358–380. doi:10.1002/hep.29086. ISSN 1527-3350. PMID 28130846.
Colli, A; Fraquelli, M; Casazza, G; Massironi, S; Colucci, A; Conte, D; Duca, P (2006 թ․ մարտ). «Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review». The American Journal of Gastroenterology. 101 (3): 513–23. doi:10.1111/j.1572-0241.2006.00467.x. PMID 16542288. S2CID 9563077.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Ertle, JM; Heider, D; Wichert, M; Keller, B; Kueper, R; Hilgard, P; Gerken, G; Schlaak, JF (2013). «A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma». Digestion. 87 (2): 121–31. doi:10.1159/000346080. PMID 23406785. S2CID 25266129.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008 թ․ մայիս). «Diagnosis and treatment of hepatocellular carcinoma». Gastroenterology. 134 (6): 1752–63. doi:10.1053/j.gastro.2008.02.090. PMID 18471552. S2CID 10418520.
Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, Wong N (2019). «Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma». J Pathol. 249 (2): 166–172. doi:10.1002/path.5313. PMID 31168847. S2CID 174815950.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Chan AW, Tong JH, Pan Y, Chan SL, Wong GL, Wong VW, Lai PB, To KF (2015). «Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome». Am J Surg Pathol. 39 (3): 304–312. doi:10.1097/pas.0000000000000376. PMID 25675010. S2CID 40384842.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Duseja, Ajay (2014 թ․ օգոստոսի 1). «Staging of Hepatocellular Carcinoma». Journal of Clinical and Experimental Hepatology. 4 (Suppl 3): S74–S79. doi:10.1016/j.jceh.2014.03.045. PMC 4284240. PMID 25755615.
Llovet JM, Brú C, Bruix J (1999). «Prognosis of hepatocellular carcinoma: the BCLC staging classification». Seminars in Liver Disease. 19 (3): 329–38. doi:10.1055/s-2007-1007122. PMID 10518312.
Kinoshita, A; Onoda, H; Fushiya, N; Koike, K; Nishino, H; Tajiri, H (2015 թ․ մարտի 27). «Staging systems for hepatocellular carcinoma: Current status and future perspectives». World Journal of Hepatology. 7 (3): 406–24. doi:10.4254/wjh.v7.i3.406. PMC 4381166. PMID 25848467.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Katyal, Sanjeev; Oliver, James H.; Peterson, Mark S.; Ferris, James V.; Carr, Brian S.; Baron, Richard L. (2000). «Extrahepatic Metastases of Hepatocellular Carcinoma». Radiology. 216 (3): 698–703. doi:10.1148/radiology.216.3.r00se24698. PMID 10966697.
Marrero, JA; Kulik, LM; Sirlin, CB; Zhu, AX; Finn, RS; Abecassis, MM; Roberts, LR; Heimbach, JK (2018 թ․ օգոստոս). «Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases» (PDF). Hepatology. 68 (2): 723–750. doi:10.1002/hep.29913. PMID 29624699. S2CID 4666537.(չաշխատող հղում)
Ma, Ka Wing; Cheung, Tan To (2016 թ․ դեկտեմբեր). «Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration». Journal of Hepatocellular Carcinoma. 4: 1–9. doi:10.2147/JHC.S96085. PMC 5207474. PMID 28097107.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Ang, Soo Fan; Ng, Elizabeth Shu-Hui; Li, Huihua; Ong, Yu-Han; Choo, Su Pin; Ngeow, Joanne; Toh, Han Chong; Lim, Kiat Hon; Yap, Hao Yun; Tan, Chee Kiat; Ooi, London Lucien Peng Jin; Chung, Alexander Yaw Fui; Chow, Pierce Kah Hoe; Foo, Kian Fong; Tan, Min-Han; Cheow, Peng Chung (2015). «The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma». PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. doi:10.1371/journal.pone.0118658. PMC 4382157. PMID 25830231.
Vitale, Alessandro; Gringeri, Enrico; Valmasoni, Michele; D'Amico, Francesco; Carraro, Amedeo; Pauletto, Alberto; D'Amico, Francesco Jr.; Polacco, Marina; D'Amico, Davide Francesco; Cillo, Umberto (2007). «Longterm results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience». Transplantation Proceedings. 39 (6): 1892–1894. doi:10.1016/j.transproceed.2007.05.031. PMID 17692645.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Cillo, Umberto; Vitale, Alessandro; Bassanello, Marco; Boccagni, Patrizia; Brolese, Alberto; Zanus, Giacomo; Burra, Patrizia; Fagiuoli, Stefano; Farinati, Fabio; Rugge, Massimo; d'Amico, Davide Francesco (2004 թ․ փետրվար). «Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma». Annals of Surgery. 239 (2): 150–9. doi:10.1097/01.sla.0000109146.72827.76. PMC 1356206. PMID 14745321.
Tanabe, KK; Curley, SA; Dodd, GD; Siperstein, AE; Goldberg, SN (2004 թ․ փետրվարի 1). «Radiofrequency ablation: the experts weigh in». Cancer. 100 (3): 641–50. doi:10.1002/cncr.11919. PMID 14745883.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Tateishi, R; Shiina, S; Teratani, T; Obi, S; Sato, S; Koike, Y; Fujishima, T; Yoshida, H; Kawabe, T; Omata, M (2005 թ․ մարտի 15). «Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases». Cancer. 103 (6): 1201–9. doi:10.1002/cncr.20892. PMID 15690326. S2CID 37178385.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Chen, Min-Shan; Li, Jin-Qing; Zheng, Yun; Guo, Rong-Ping; Liang, Hui-Hong; Zhang, Ya-Qi; Lin, Xiao-Jun; Lau, Wan Y (2006). «A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma». Annals of Surgery. 243 (3): 321–8. doi:10.1097/01.sla.0000201480.65519.b8. PMC 1448947. PMID 16495695.
Yamamoto, Junji; Okada, Shuichi; Shimada, Kazuaki; Okusaka, Takushi; Yamasaki, Susumu; Ueno, Hideki; Kosuge, Tomoo (2001). «Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection». Hepatology. 34 (4): 707–713. doi:10.1053/jhep.2001.27950. PMID 11584366.

harvard.edu

ui.adsabs.harvard.edu

Ang, Soo Fan; Ng, Elizabeth Shu-Hui; Li, Huihua; Ong, Yu-Han; Choo, Su Pin; Ngeow, Joanne; Toh, Han Chong; Lim, Kiat Hon; Yap, Hao Yun; Tan, Chee Kiat; Ooi, London Lucien Peng Jin; Chung, Alexander Yaw Fui; Chow, Pierce Kah Hoe; Foo, Kian Fong; Tan, Min-Han; Cheow, Peng Chung (2015). «The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma». PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. doi:10.1371/journal.pone.0118658. PMC 4382157. PMID 25830231.

hepatocellular.org

«Hepatocellular Carcinoma and Diseases». Վերցված է 2010 թ․ մայիսի 12-ին.

iarc.fr

gco.iarc.fr

«Global Cancer Observatory». gco.iarc.fr. Վերցված է 2021 թ․ հունիսի 24-ին.

lecturio.com

«Benign Liver Tumors». The Lecturio Medical Concept Library. Վերցված է 2021 թ․ հուլիսի 4-ին.

mayoclinic.com

«Liver cancer overview». Mayo Clinic.

medicinespecifics.com

«NAFLD vs. NASH». Medicine Specifics (ամերիկյան անգլերեն). 2019 թ․ նոյեմբերի 11. Վերցված է 2021 թ․ հունիսի 22-ին.

medscape.com

emedicine.medscape.com

«Pathophysiology». 2019 թ․ նոյեմբերի 10. Վերցված է 2010 թ․ մայիսի 12-ին. {{cite journal}}: Cite journal requires |journal= (օգնություն)

medscape.com

«What is the Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma (HCC) staging?». www.medscape.com.

nih.gov

pubmed.ncbi.nlm.nih.gov

Forner A, Llovet JM, Bruix J (2012). «Hepatocellular carcinoma». The Lancet. 379 (9822): 1245–1255. doi:10.1016/S0140-6736(11)61347-0. PMID 22353262. S2CID 24927898.
Heidelbaugh, Joel J.; Bruderly, Michael (2006 թ․ սեպտեմբերի 1). «Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation». American Family Physician. 74 (5): 756–762. ISSN 0002-838X. PMID 16970019.
Alter MJ (2007). «Epidemiology of hepatitis C virus infection». World Journal of Gastroenterology. 13 (17): 2436–41. doi:10.3748/wjg.v13.i17.2436. PMC 4146761. PMID 17552026.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
White DL, Kanwal F, El-Serag HB (2012). «Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review». Clinical Gastroenterology and Hepatology. 10 (12): 1342–59. doi:10.1016/j.cgh.2012.10.001. PMC 3501546. PMID 23041539.
El–Serag HB; Hampel H; Javadi F (2006). «the association between diabetes and hepatocellular carcinoma: a systematic review of epidemiological evidence». Clinical Gastroenterology and Hepatology. 4 (3): 369–380. doi:10.1016/j.cgh.2005.12.007. PMID 16527702. «Diabetes is associated with an increased risk for HCC. However, more research is required to examine issues related to the duration and treatment of diabetes, and confounding by diet and obesity»
Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC (2002). «Molecular pathogenesis of human hepatocellular carcinoma». Toxicology. 181–182: 43–47. doi:10.1016/S0300-483X(02)00253-6. PMID 12505283. «Recent studies in our laboratory have identified several potential factors that may contribute to the pathogenesis of HCC...For example, oxyradical overload diseases such as Wilson disease and hemochromatosis result in the generation of oxygen/nitrogen species that can cause mutations in the p53 tumour suppressor gene»
Cheng W, Govindarajan S, Redeker A (1992). «Hepatocellular carcinoma in a case of Wilson's disease». Liver International. 12 (1): 42–45. doi:10.1111/j.1600-0676.1992.tb00553.x. PMID 1314321. «The patient described here was the oldest and only the third female patient with hepatocellular carcinoma complicating Wilson's disease to be reported in the literature»
Wilkinson ML, Portmann B, Williams R (1983). «Wilson's disease and hepatocellular carcinoma: possible protective role of copper». Gut. 24 (8): 767–771. doi:10.1136/gut.24.8.767. PMC 1420230. PMID 6307837. «As copper has been shown to protect against chemically induced hepatocellular carcinoma in rats, this may be the reason for the extreme rarity of hepatocellular carcinoma in patients with Wilson's disease and possibly in other liver diseases with hepatic copper overload»
Shetty, Shrimati; Sharma, Nitika; Ghosh, Kanjaksha (2016 թ․ մարտի 1). «Epidemiology of hepatocellular carcinoma (HCC) in hemophilia». Critical Reviews in Oncology/Hematology (անգլերեն). 99: 129–133. doi:10.1016/j.critrevonc.2015.12.009. ISSN 1040-8428. PMID 26754251.
Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M (2011). «Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures». Journal of Epidemiology. 21 (6): 401–416. doi:10.2188/jea.JE20100190. PMC 3899457. PMID 22041528.
Balogh J, Victor D, Asham E, Burroughs S, Boktour M, Saharia A, Li X, Ghobrial M, Monsour H (2016). «Hepatocellular carcinoma: a review». Journal of Hepatocellular Carcinoma. 3: 41–53. doi:10.2147/JHC.S61146. PMC 5063561. PMID 27785449.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN (2010). «Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma». Cancer. 116 (8): 1938–1946. doi:10.1002/cncr.24982. PMC 4123320. PMID 20166205. «Diabetes appears to increase the risk of HCC, and such risk is correlated with a long duration of diabetes. Relying on dietary control and treatment with sulfonylureas or insulin were found to confer the highest magnitude of HCC risk, whereas treatment with biguanides or thiazolidinediones was associated with a 70% HCC risk reduction among diabetics.»
Donadon, Valter (2009). «Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease». World Journal of Gastroenterology. 15 (20): 2506–11. doi:10.3748/wjg.15.2506. PMC 2686909. PMID 19469001. «Our study confirms that type 2 diabetes mellitus is an independent risk factor for HCC and pre-exists in the majority of HCC patients. Moreover, in male patients with type 2 diabetes mellitus, our data shows a direct association of HCC with insulin and sulphanylureas treatment and an inverse relationship with metformin therapy.»{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Donadon V, Balbi M, Ghersetti M, և այլք: (2009). «Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease». World Journal of Gastroenterology. 15 (20): 2506–11. doi:10.3748/wjg.15.2506. PMC 2686909. PMID 19469001.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Siegel A, Zhu AX (2009). «Metabolic Syndrome and hepatocellular carcinoma». Cancer. 115 (24): 5651–5661. doi:10.1002/cncr.24687. PMC 3397779. PMID 19834957. «The majority of 'cryptogenic' HCC in the United States is attributed to nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome... It is predicted that metabolic syndrome will lead to large increases in the incidence of HCC over the next decades. A better understanding of the relation between these two diseases ultimately should lead to improved screening and treatment options for patients with HCC.»
Stickely F, Hellerbrand C (2010). «Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications». Gut. 59 (10): 1303–1307. doi:10.1136/gut.2009.199661. PMID 20650925. S2CID 31016985. «Based on the known association of NAFLD with IR and MS, approximately two-thirds of the patients were obese and/or diabetic, 4 and a remarkable 25% of these patients had no cirrhosis... Therefore, it is particularly worrying that the most persuasive evidence for an association between NAFLD and HCC derives from studies on the risk of HCC in patients with metabolic syndrome»
Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H (2006). «Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells». Biochemical Pharmacology. 71 (10): 1435–1448. doi:10.1016/j.bcp.2006.02.006. PMID 16530734. «Inhibition of IGF-1R tyrosine kinase (IGF-1R-TK) by NVP-AEW541 induces growth inhibition, apoptosis and cell cycle arrest in human HCC cell lines without accompanying cytotoxicity. Thus, IGF-1R-TK inhibition may be a promising novel treatment approach in HCC.»
Huynh H, Chow PK, Ooi LL, Soo KC (2002). «A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation». Cell Growth & Differentiation. 13 (3): 115–122. PMID 11959812. Արխիվացված է օրիգինալից 2021 թ․ ապրիլի 15-ին. Վերցված է 2023 թ․ հունվարի 28-ին. «Our data indicate that loss of autocrine/paracrine IGFBP-3 loops may lead to HCC tumor growth and suggest that modulating production of the IGFs, IGFBP-3, and IGF-IR may represent a novel approach in the treatment of HCC.»
Martin NM, Abu Dayyeh BK, Chung RT (2008). «Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage». World Journal of Gastroenterology. 14 (28): 4573–4575. doi:10.3748/wjg.14.4573. PMC 2731289. PMID 18680242. «This is the first reported case of hepatic adenoma re-growth with recidivistic steroid abuse, complicated by life-threatening hemorrhage.»{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Gorayski P, Thompson CH, Subhash HS, Thomas AC (2007). «Hepatocellular carcinoma associated with recreational anabolic steroid use». British Journal of Sports Medicine. 42 (1): 74–75. doi:10.1136/bjsm.2007.03932. PMID 18178686. S2CID 21900098. «Malignant transformation to HCC from a pre-existing hepatic adenoma confirmed by immunohistochemical study has previously not been reported in athletes taking anabolic steroids. Further studies using screening programmes to identify high-risk individuals are recommended.»
Shibata T, Aburatani H (2014). «Exploration of liver cancer genomes». Nat Rev Gastroenterol Hepatol. 11 (6): 340–9. doi:10.1038/nrgastro.2014.6. PMID 24473361. S2CID 8611393.
Chien-Jen Chen; Hwai-I. Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H. Iloeje (2006). «Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level». JAMA. 295 (1): 65–73. doi:10.1001/jama.295.1.65. PMID 16391218.
Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT (2014). «Involvement of DNA damage response pathways in hepatocellular carcinoma». Biomed Res Int. 2014: 1–18. doi:10.1155/2014/153867. PMC 4022277. PMID 24877058.
Nishida N, Kudo M (2013). «Oxidative stress and epigenetic instability in human hepatocarcinogenesis». Dig Dis. 31 (5–6): 447–53. doi:10.1159/000355243. PMID 24281019.
Heimbach, Julie K.; Kulik, Laura M.; Finn, Richard; Sirlin, Claude B.; Abecassis, Michael; Roberts, Lewis R.; Zhu, Andrew; Murad, M. Hassan; Marrero, Jorge (2017 թ․ հունվարի 1). «Aasld guidelines for the treatment of hepatocellular carcinoma». Hepatology (անգլերեն). 67 (1): 358–380. doi:10.1002/hep.29086. ISSN 1527-3350. PMID 28130846.
Colli, A; Fraquelli, M; Casazza, G; Massironi, S; Colucci, A; Conte, D; Duca, P (2006 թ․ մարտ). «Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review». The American Journal of Gastroenterology. 101 (3): 513–23. doi:10.1111/j.1572-0241.2006.00467.x. PMID 16542288. S2CID 9563077.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Ertle, JM; Heider, D; Wichert, M; Keller, B; Kueper, R; Hilgard, P; Gerken, G; Schlaak, JF (2013). «A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma». Digestion. 87 (2): 121–31. doi:10.1159/000346080. PMID 23406785. S2CID 25266129.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008 թ․ մայիս). «Diagnosis and treatment of hepatocellular carcinoma». Gastroenterology. 134 (6): 1752–63. doi:10.1053/j.gastro.2008.02.090. PMID 18471552. S2CID 10418520.
Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, Wong N (2019). «Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma». J Pathol. 249 (2): 166–172. doi:10.1002/path.5313. PMID 31168847. S2CID 174815950.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Chan AW, Tong JH, Pan Y, Chan SL, Wong GL, Wong VW, Lai PB, To KF (2015). «Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome». Am J Surg Pathol. 39 (3): 304–312. doi:10.1097/pas.0000000000000376. PMID 25675010. S2CID 40384842.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Duseja, Ajay (2014 թ․ օգոստոսի 1). «Staging of Hepatocellular Carcinoma». Journal of Clinical and Experimental Hepatology. 4 (Suppl 3): S74–S79. doi:10.1016/j.jceh.2014.03.045. PMC 4284240. PMID 25755615.
Llovet JM, Brú C, Bruix J (1999). «Prognosis of hepatocellular carcinoma: the BCLC staging classification». Seminars in Liver Disease. 19 (3): 329–38. doi:10.1055/s-2007-1007122. PMID 10518312.
Kinoshita, A; Onoda, H; Fushiya, N; Koike, K; Nishino, H; Tajiri, H (2015 թ․ մարտի 27). «Staging systems for hepatocellular carcinoma: Current status and future perspectives». World Journal of Hepatology. 7 (3): 406–24. doi:10.4254/wjh.v7.i3.406. PMC 4381166. PMID 25848467.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Katyal, Sanjeev; Oliver, James H.; Peterson, Mark S.; Ferris, James V.; Carr, Brian S.; Baron, Richard L. (2000). «Extrahepatic Metastases of Hepatocellular Carcinoma». Radiology. 216 (3): 698–703. doi:10.1148/radiology.216.3.r00se24698. PMID 10966697.
Marrero, JA; Kulik, LM; Sirlin, CB; Zhu, AX; Finn, RS; Abecassis, MM; Roberts, LR; Heimbach, JK (2018 թ․ օգոստոս). «Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases» (PDF). Hepatology. 68 (2): 723–750. doi:10.1002/hep.29913. PMID 29624699. S2CID 4666537.(չաշխատող հղում)
Ma, Ka Wing; Cheung, Tan To (2016 թ․ դեկտեմբեր). «Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration». Journal of Hepatocellular Carcinoma. 4: 1–9. doi:10.2147/JHC.S96085. PMC 5207474. PMID 28097107.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Ang, Soo Fan; Ng, Elizabeth Shu-Hui; Li, Huihua; Ong, Yu-Han; Choo, Su Pin; Ngeow, Joanne; Toh, Han Chong; Lim, Kiat Hon; Yap, Hao Yun; Tan, Chee Kiat; Ooi, London Lucien Peng Jin; Chung, Alexander Yaw Fui; Chow, Pierce Kah Hoe; Foo, Kian Fong; Tan, Min-Han; Cheow, Peng Chung (2015). «The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma». PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. doi:10.1371/journal.pone.0118658. PMC 4382157. PMID 25830231.
Vitale, Alessandro; Gringeri, Enrico; Valmasoni, Michele; D'Amico, Francesco; Carraro, Amedeo; Pauletto, Alberto; D'Amico, Francesco Jr.; Polacco, Marina; D'Amico, Davide Francesco; Cillo, Umberto (2007). «Longterm results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience». Transplantation Proceedings. 39 (6): 1892–1894. doi:10.1016/j.transproceed.2007.05.031. PMID 17692645.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Cillo, Umberto; Vitale, Alessandro; Bassanello, Marco; Boccagni, Patrizia; Brolese, Alberto; Zanus, Giacomo; Burra, Patrizia; Fagiuoli, Stefano; Farinati, Fabio; Rugge, Massimo; d'Amico, Davide Francesco (2004 թ․ փետրվար). «Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma». Annals of Surgery. 239 (2): 150–9. doi:10.1097/01.sla.0000109146.72827.76. PMC 1356206. PMID 14745321.
Tanabe, KK; Curley, SA; Dodd, GD; Siperstein, AE; Goldberg, SN (2004 թ․ փետրվարի 1). «Radiofrequency ablation: the experts weigh in». Cancer. 100 (3): 641–50. doi:10.1002/cncr.11919. PMID 14745883.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Tateishi, R; Shiina, S; Teratani, T; Obi, S; Sato, S; Koike, Y; Fujishima, T; Yoshida, H; Kawabe, T; Omata, M (2005 թ․ մարտի 15). «Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases». Cancer. 103 (6): 1201–9. doi:10.1002/cncr.20892. PMID 15690326. S2CID 37178385.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Chen, Min-Shan; Li, Jin-Qing; Zheng, Yun; Guo, Rong-Ping; Liang, Hui-Hong; Zhang, Ya-Qi; Lin, Xiao-Jun; Lau, Wan Y (2006). «A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma». Annals of Surgery. 243 (3): 321–8. doi:10.1097/01.sla.0000201480.65519.b8. PMC 1448947. PMID 16495695.
Yamamoto, Junji; Okada, Shuichi; Shimada, Kazuaki; Okusaka, Takushi; Yamasaki, Susumu; Ueno, Hideki; Kosuge, Tomoo (2001). «Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection». Hepatology. 34 (4): 707–713. doi:10.1053/jhep.2001.27950. PMID 11584366.

ncbi.nlm.nih.gov

Alter MJ (2007). «Epidemiology of hepatitis C virus infection». World Journal of Gastroenterology. 13 (17): 2436–41. doi:10.3748/wjg.v13.i17.2436. PMC 4146761. PMID 17552026.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
White DL, Kanwal F, El-Serag HB (2012). «Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review». Clinical Gastroenterology and Hepatology. 10 (12): 1342–59. doi:10.1016/j.cgh.2012.10.001. PMC 3501546. PMID 23041539.
Wilkinson ML, Portmann B, Williams R (1983). «Wilson's disease and hepatocellular carcinoma: possible protective role of copper». Gut. 24 (8): 767–771. doi:10.1136/gut.24.8.767. PMC 1420230. PMID 6307837. «As copper has been shown to protect against chemically induced hepatocellular carcinoma in rats, this may be the reason for the extreme rarity of hepatocellular carcinoma in patients with Wilson's disease and possibly in other liver diseases with hepatic copper overload»
Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M (2011). «Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures». Journal of Epidemiology. 21 (6): 401–416. doi:10.2188/jea.JE20100190. PMC 3899457. PMID 22041528.
Balogh J, Victor D, Asham E, Burroughs S, Boktour M, Saharia A, Li X, Ghobrial M, Monsour H (2016). «Hepatocellular carcinoma: a review». Journal of Hepatocellular Carcinoma. 3: 41–53. doi:10.2147/JHC.S61146. PMC 5063561. PMID 27785449.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN (2010). «Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma». Cancer. 116 (8): 1938–1946. doi:10.1002/cncr.24982. PMC 4123320. PMID 20166205. «Diabetes appears to increase the risk of HCC, and such risk is correlated with a long duration of diabetes. Relying on dietary control and treatment with sulfonylureas or insulin were found to confer the highest magnitude of HCC risk, whereas treatment with biguanides or thiazolidinediones was associated with a 70% HCC risk reduction among diabetics.»
Donadon, Valter (2009). «Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease». World Journal of Gastroenterology. 15 (20): 2506–11. doi:10.3748/wjg.15.2506. PMC 2686909. PMID 19469001. «Our study confirms that type 2 diabetes mellitus is an independent risk factor for HCC and pre-exists in the majority of HCC patients. Moreover, in male patients with type 2 diabetes mellitus, our data shows a direct association of HCC with insulin and sulphanylureas treatment and an inverse relationship with metformin therapy.»{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Donadon V, Balbi M, Ghersetti M, և այլք: (2009). «Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease». World Journal of Gastroenterology. 15 (20): 2506–11. doi:10.3748/wjg.15.2506. PMC 2686909. PMID 19469001.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Siegel A, Zhu AX (2009). «Metabolic Syndrome and hepatocellular carcinoma». Cancer. 115 (24): 5651–5661. doi:10.1002/cncr.24687. PMC 3397779. PMID 19834957. «The majority of 'cryptogenic' HCC in the United States is attributed to nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome... It is predicted that metabolic syndrome will lead to large increases in the incidence of HCC over the next decades. A better understanding of the relation between these two diseases ultimately should lead to improved screening and treatment options for patients with HCC.»
Martin NM, Abu Dayyeh BK, Chung RT (2008). «Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage». World Journal of Gastroenterology. 14 (28): 4573–4575. doi:10.3748/wjg.14.4573. PMC 2731289. PMID 18680242. «This is the first reported case of hepatic adenoma re-growth with recidivistic steroid abuse, complicated by life-threatening hemorrhage.»{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT (2014). «Involvement of DNA damage response pathways in hepatocellular carcinoma». Biomed Res Int. 2014: 1–18. doi:10.1155/2014/153867. PMC 4022277. PMID 24877058.
Duseja, Ajay (2014 թ․ օգոստոսի 1). «Staging of Hepatocellular Carcinoma». Journal of Clinical and Experimental Hepatology. 4 (Suppl 3): S74–S79. doi:10.1016/j.jceh.2014.03.045. PMC 4284240. PMID 25755615.
Kinoshita, A; Onoda, H; Fushiya, N; Koike, K; Nishino, H; Tajiri, H (2015 թ․ մարտի 27). «Staging systems for hepatocellular carcinoma: Current status and future perspectives». World Journal of Hepatology. 7 (3): 406–24. doi:10.4254/wjh.v7.i3.406. PMC 4381166. PMID 25848467.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Ma, Ka Wing; Cheung, Tan To (2016 թ․ դեկտեմբեր). «Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration». Journal of Hepatocellular Carcinoma. 4: 1–9. doi:10.2147/JHC.S96085. PMC 5207474. PMID 28097107.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Ang, Soo Fan; Ng, Elizabeth Shu-Hui; Li, Huihua; Ong, Yu-Han; Choo, Su Pin; Ngeow, Joanne; Toh, Han Chong; Lim, Kiat Hon; Yap, Hao Yun; Tan, Chee Kiat; Ooi, London Lucien Peng Jin; Chung, Alexander Yaw Fui; Chow, Pierce Kah Hoe; Foo, Kian Fong; Tan, Min-Han; Cheow, Peng Chung (2015). «The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma». PLOS ONE. 10 (4): e0118658. Bibcode:2015PLoSO..1018658A. doi:10.1371/journal.pone.0118658. PMC 4382157. PMID 25830231.
Cillo, Umberto; Vitale, Alessandro; Bassanello, Marco; Boccagni, Patrizia; Brolese, Alberto; Zanus, Giacomo; Burra, Patrizia; Fagiuoli, Stefano; Farinati, Fabio; Rugge, Massimo; d'Amico, Davide Francesco (2004 թ․ փետրվար). «Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma». Annals of Surgery. 239 (2): 150–9. doi:10.1097/01.sla.0000109146.72827.76. PMC 1356206. PMID 14745321.
Chen, Min-Shan; Li, Jin-Qing; Zheng, Yun; Guo, Rong-Ping; Liang, Hui-Hong; Zhang, Ya-Qi; Lin, Xiao-Jun; Lau, Wan Y (2006). «A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma». Annals of Surgery. 243 (3): 321–8. doi:10.1097/01.sla.0000201480.65519.b8. PMC 1448947. PMID 16495695.

nlm.nih.gov

«Prevention». Վերցված է 2010 թ․ մայիսի 12-ին.
Hepatocellular carcinoma Արխիվացված 2016-07-05 Wayback Machine MedlinePlus, Medical Encyclopedia

pathologyatlas.ro

Hepatocellular carcinoma (Photo) Արխիվացված 2021-11-01 Wayback Machine ATLAS OF PATHOLOGY

semanticscholar.org

api.semanticscholar.org

Forner A, Llovet JM, Bruix J (2012). «Hepatocellular carcinoma». The Lancet. 379 (9822): 1245–1255. doi:10.1016/S0140-6736(11)61347-0. PMID 22353262. S2CID 24927898.
Stickely F, Hellerbrand C (2010). «Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications». Gut. 59 (10): 1303–1307. doi:10.1136/gut.2009.199661. PMID 20650925. S2CID 31016985. «Based on the known association of NAFLD with IR and MS, approximately two-thirds of the patients were obese and/or diabetic, 4 and a remarkable 25% of these patients had no cirrhosis... Therefore, it is particularly worrying that the most persuasive evidence for an association between NAFLD and HCC derives from studies on the risk of HCC in patients with metabolic syndrome»
Gorayski P, Thompson CH, Subhash HS, Thomas AC (2007). «Hepatocellular carcinoma associated with recreational anabolic steroid use». British Journal of Sports Medicine. 42 (1): 74–75. doi:10.1136/bjsm.2007.03932. PMID 18178686. S2CID 21900098. «Malignant transformation to HCC from a pre-existing hepatic adenoma confirmed by immunohistochemical study has previously not been reported in athletes taking anabolic steroids. Further studies using screening programmes to identify high-risk individuals are recommended.»
Shibata T, Aburatani H (2014). «Exploration of liver cancer genomes». Nat Rev Gastroenterol Hepatol. 11 (6): 340–9. doi:10.1038/nrgastro.2014.6. PMID 24473361. S2CID 8611393.
Colli, A; Fraquelli, M; Casazza, G; Massironi, S; Colucci, A; Conte, D; Duca, P (2006 թ․ մարտ). «Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review». The American Journal of Gastroenterology. 101 (3): 513–23. doi:10.1111/j.1572-0241.2006.00467.x. PMID 16542288. S2CID 9563077.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Ertle, JM; Heider, D; Wichert, M; Keller, B; Kueper, R; Hilgard, P; Gerken, G; Schlaak, JF (2013). «A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma». Digestion. 87 (2): 121–31. doi:10.1159/000346080. PMID 23406785. S2CID 25266129.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008 թ․ մայիս). «Diagnosis and treatment of hepatocellular carcinoma». Gastroenterology. 134 (6): 1752–63. doi:10.1053/j.gastro.2008.02.090. PMID 18471552. S2CID 10418520.
Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, Wong N (2019). «Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma». J Pathol. 249 (2): 166–172. doi:10.1002/path.5313. PMID 31168847. S2CID 174815950.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Chan AW, Tong JH, Pan Y, Chan SL, Wong GL, Wong VW, Lai PB, To KF (2015). «Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome». Am J Surg Pathol. 39 (3): 304–312. doi:10.1097/pas.0000000000000376. PMID 25675010. S2CID 40384842.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)
Marrero, JA; Kulik, LM; Sirlin, CB; Zhu, AX; Finn, RS; Abecassis, MM; Roberts, LR; Heimbach, JK (2018 թ․ օգոստոս). «Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases» (PDF). Hepatology. 68 (2): 723–750. doi:10.1002/hep.29913. PMID 29624699. S2CID 4666537.(չաշխատող հղում)
Tateishi, R; Shiina, S; Teratani, T; Obi, S; Sato, S; Koike, Y; Fujishima, T; Yoshida, H; Kawabe, T; Omata, M (2005 թ․ մարտի 15). «Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases». Cancer. 103 (6): 1201–9. doi:10.1002/cncr.20892. PMID 15690326. S2CID 37178385.{{cite journal}}: CS1 սպաս․ բազմաթիվ անուններ: authors list (link)

semanticscholar.org

El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008 թ․ մայիս). «Diagnosis and treatment of hepatocellular carcinoma». Gastroenterology. 134 (6): 1752–63. doi:10.1053/j.gastro.2008.02.090. PMID 18471552. S2CID 10418520.

uptodate.com

«Clinical features and diagnosis of primary hepatocellular carcinoma». UptoDate. Վերցված է 2014 թ․ փետրվարի 4-ին.

web.archive.org

Huynh H, Chow PK, Ooi LL, Soo KC (2002). «A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation». Cell Growth & Differentiation. 13 (3): 115–122. PMID 11959812. Արխիվացված է օրիգինալից 2021 թ․ ապրիլի 15-ին. Վերցված է 2023 թ․ հունվարի 28-ին. «Our data indicate that loss of autocrine/paracrine IGFBP-3 loops may lead to HCC tumor growth and suggest that modulating production of the IGFs, IGFBP-3, and IGF-IR may represent a novel approach in the treatment of HCC.»
«Li-Rads». Արխիվացված է օրիգինալից 2017 թ․ հուլիսի 11-ին. Վերցված է 2014 թ․ փետրվարի 4-ին.
Hepatocellular carcinoma (Photo) Արխիվացված 2021-11-01 Wayback Machine ATLAS OF PATHOLOGY
«Hepatitis B: Prevention and treatment». Արխիվացված է օրիգինալից 2013 թ․ հուլիսի 24-ին. Վերցված է 2013 թ․ օգոստոսի 28-ին. "WHO aims at controlling HBV worldwide to decrease the incidence of HBV-related chronic liver disease, cirrhosis, and hepatocellular carcinoma. by integrating HB vaccination into routine infant (and possibly adolescent) immunization programs."
Hepatocellular carcinoma Արխիվացված 2016-07-05 Wayback Machine MedlinePlus, Medical Encyclopedia
Table 37.2 Արխիվացված 2020-02-24 Wayback Machine in: Sternberg, Stephen (2012). Sternberg's diagnostic surgical pathology. Place of publication not identified: LWW. ISBN 978-1-4511-5289-0. OCLC 953861627.

who.int

«Hepatitis B: Prevention and treatment». Արխիվացված է օրիգինալից 2013 թ․ հուլիսի 24-ին. Վերցված է 2013 թ․ օգոստոսի 28-ին. "WHO aims at controlling HBV worldwide to decrease the incidence of HBV-related chronic liver disease, cirrhosis, and hepatocellular carcinoma. by integrating HB vaccination into routine infant (and possibly adolescent) immunization programs."
«WHO Disease and injury country estimates». World Health Organization. 2009. Վերցված է 2009 թ․ նոյեմբերի 11-ին.
«Cancer». World Health Organization. 2006 թ․ փետրվար. Վերցված է 2007 թ․ մայիսի 24-ին.

worldcat.org

Heidelbaugh, Joel J.; Bruderly, Michael (2006 թ․ սեպտեմբերի 1). «Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation». American Family Physician. 74 (5): 756–762. ISSN 0002-838X. PMID 16970019.
Shetty, Shrimati; Sharma, Nitika; Ghosh, Kanjaksha (2016 թ․ մարտի 1). «Epidemiology of hepatocellular carcinoma (HCC) in hemophilia». Critical Reviews in Oncology/Hematology (անգլերեն). 99: 129–133. doi:10.1016/j.critrevonc.2015.12.009. ISSN 1040-8428. PMID 26754251.
Heimbach, Julie K.; Kulik, Laura M.; Finn, Richard; Sirlin, Claude B.; Abecassis, Michael; Roberts, Lewis R.; Zhu, Andrew; Murad, M. Hassan; Marrero, Jorge (2017 թ․ հունվարի 1). «Aasld guidelines for the treatment of hepatocellular carcinoma». Hepatology (անգլերեն). 67 (1): 358–380. doi:10.1002/hep.29086. ISSN 1527-3350. PMID 28130846.
Table 37.2 Արխիվացված 2020-02-24 Wayback Machine in: Sternberg, Stephen (2012). Sternberg's diagnostic surgical pathology. Place of publication not identified: LWW. ISBN 978-1-4511-5289-0. OCLC 953861627.

zenodo.org

Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC (2002). «Molecular pathogenesis of human hepatocellular carcinoma». Toxicology. 181–182: 43–47. doi:10.1016/S0300-483X(02)00253-6. PMID 12505283. «Recent studies in our laboratory have identified several potential factors that may contribute to the pathogenesis of HCC...For example, oxyradical overload diseases such as Wilson disease and hemochromatosis result in the generation of oxygen/nitrogen species that can cause mutations in the p53 tumour suppressor gene»